linjc16/ctgov huggingface dataset:
Two Pieces of Fruit to Type 2 Diabetics?

Study Overview
=================
Brief Summary
-----------------
It has been questioned whether patients with type 2 diabetes who are advised to restrict their fruit consumption to two or less pieces of fruits daily have better outcomes (HbA1c, body weight, fruit intake and serum lipids) after three months compared to patients with type 2 diabetes who are advised to eat at least two pieces of fruits. To the investigators' knowledge, no randomized controlled trial has evaluated this. The investigators therefore perform a randomized controlled trial including 76 patients with type 2 diabetes to investigate this. The investigators' hypothesis is that: Type 2 diabetics who are advised to restrict their fruit consumption have the same Hba1c three months after an initially dietary treatment as type 2 diabetics who are advised not to restrict their fruit consumption.

Official Title
-----------------
Two Pieces of Fruit to Type 2 Diabetics?

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Behavioral: dietary treatment
* Behavioral: dietary treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients refered from a general practitioner Exclusion Criteria: no Hba1c when refered Hba1c lower than 5% or higher than 12% patients that require a translator patients with severe cardiovascular, renal or endocrine disease psychiatric patients pregnant patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Fruit restricted<br>Type 2 diabetics are advised to restrict their fruit intake to two pieces or less daily. | Behavioral: dietary treatment<br>* A standard dietary treatment except that they are advised to restrict their fruit intake.<br>|
| Active Comparator: Fruit ad libitum<br>Type 2 diabetics are advised to eat at least two pieces of fruits daily | Behavioral: dietary treatment<br>* A standard dietary treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Hba1c |  | three months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in bodyweight |  | three months | 
| change in serum lipids |  | three months | 
| change in fruit intake |  | three months |
Heritability and Genetics of Fat Taste

Study Overview
=================
Brief Summary
-----------------
The investigators seek to determine how genetics and the environment influence the ability to taste and smell fat. The investigators believe that people who consume higher fat diets and people who have higher body fat levels are less able to taste and smell fat. The investigators expect to see that people who are less able to taste and smell fat will share certain genetic differences.

Official Title
-----------------
Heritability and Genetics of Fat Taste

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willingness to participate Ages 8 and older Exclusion Criteria: Younger than 8 years old

Ages Eligible for Study
-----------------
Minimum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All participants<br>All individuals visiting the museum who want to participate and sign a consent form. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Taste sensitivity | Intensity ratings of linoleic acid will be measured using a visual analog scale. | At visit | 
| Genotype | Various SNPs related to taste will be genotyped. | At visit | 
| Anthropometric measures | BMI, % body fat, % body water will be measured using BIA. | At visit | 
| Dietary data | Exposure to high-fat foods and information from most recent meal (optional) will be evaluated. | At visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Taste responses of healthy individuals
Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Esophageal Motility Disorders

Study Overview
=================
Brief Summary
-----------------
Spastic esophageal motility disorders induced significant symptoms including dysphagia, retrosternal pain and regurgitation. Per oral endoscopic myotomy (P.O.E.M.) is a novel approach to perform myotomy through the esophagus with long submucosal tunnel. This study aimed to investigate the feasibility and safety of P.O.E.M. and translate the techniques from animal study to clinical practice in human.

Official Title
-----------------
Prospective Study on the Feasibility and Effectiveness of Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders

Conditions
-----------------
Achalasia, Hypertensive LES

Intervention / Treatment
-----------------
* Procedure: Per Oral Endoscopic Myotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with age ranged 18 to 80 who had primary esophageal motility disorders will be recruited. The primary motility disorders included: Achalasia, hypertensive LES, Nutcracker esophagus and Diffuse esophageal spasm. Exclusion Criteria: Patients will be excluded from this study with the followings - Pregnancy Informed consent not available Previous history of esophagectomy or mediastinal surgery Previous history of endoscopic resection for early esophageal cancers, including endoscopic mucosal resection and endoscopic submucosal dissection End-stage Achalasia with dilated esophagus more than 6cm on Barium swallow

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: POEM<br>Per Oral Endoscopic Myotomy | Procedure: Per Oral Endoscopic Myotomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dysphagia score before and after P.O.E.M. |  | From 1st day after POEM to within 2 weeks after POEM | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eckardt score before and after P.O.E.M. |  | Before and 1 month after POEM | 
| Post-operative pain |  | From Day 1 to until 2 weeks after POEM | 
| Operative time |  | Up to 24 hours | 
| Hospital stay |  | From day of admission till up to 30 days | 
| Perioperative complication |  | 30 days after operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Achalasia, Hypertensive LES
Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi Syndrome

Study Overview
=================
Brief Summary
-----------------
Context: Prader-Willi syndrome (PWS) is a genetic disorder characterized by childhood-onset obesity and endocrine dysfunction that leads to cardiovascular disability and early death within the first 3 decades of life. Objectives: To assess the significance of risk factors for future disabilities, carotid artery intima-media thickness (IMT) was measured and correlated with known atherosclerotic risk factors in 27 children with PWS and 24 age-, sex-, and body mass index (BMI)-adjusted controls.

Detailed Description
-----------------
Main outcome measures: Correlation of IMT with age, standard deviation score of BMI (BMI-SDS), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), C-reactive protein, HOMA-IR and ghrelin.

Official Title
-----------------
Correlation Between Hyperghrelinemia and Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndrome

Conditions
-----------------
Prader-Willi Syndrome, Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: obesity with PWS Exclusion Criteria: chronic disease

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intima-media thickness, Ghrelin, Prader-Willi syndrome
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

Detailed Description
-----------------
non small cell lung cancer (non squamous carcinoma) ECOG 0-1 from 18-75 years old

Official Title
-----------------
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

Conditions
-----------------
Non Small Cell Lung Cancer, Brain Metastasis

Intervention / Treatment
-----------------
* Other: bevacizumab, standard chemotherapy and radiation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non squamous cell non small cell lung cancer with measurable disease ECOG 0-1 Exclusion Criteria: - patients received surgery in recent 4 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS |  | 18 months |
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).

Official Title
-----------------
A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Conditions
-----------------
Kidney Disease, Chronic Kidney Disease

Intervention / Treatment
-----------------
* Drug: Cinacalcet HCl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic Kidney Disease patients not receiving dialysis with: - An iPTH greater than 100 pg/mL [10.6 pmol/L] for subjects with stage 3 CKD or greater than or equal to 160 pg/mL [17.0 pmol/L] for subjects with stage 4 CKD; - A serum calcium greater than 9.0 mg/dL [2.25 mmol/L]; - An estimated GFR less than or equal to 59 mL/min and greater than or equal to 15 mL/min. Exclusion Criteria: - Have an unstable medical condition, defined as having been hospitalized within 30 days before day 1, or otherwise unstable in the judgment of the investigator. - Experienced a myocardial infarction (MI) within 3 months before day 1. - Likely to initiate dialysis (in the opinion of the investigator) or are scheduled to undergo renal transplantation within 28 weeks after day 1. - Received active vitamin D therapy (i.e., 1-hydroxylated metabolites of vitamin D) for less than 30 days before day 1 or required a change in active vitamin D brand or dose level within 30 days before day 1 (for patients prescribed active vitamin D).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cinacalcet HCl|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of subjects with a mean reduction of greater than or equal to 30% in iPTH at 32 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in iPTH at 32 weeks. |  |  | 
| Safety and tolerability of cinacalcet at 32 weeks. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sensipar®, Mimpara®, Cinacalcet, Calcimimetic, Chronic Kidney Disease
Exercise and Cognitive-psychosocial Functions in Men With Prostate Cancer Receiving Androgen Depletion Therapy

Study Overview
=================
Brief Summary
-----------------
The objective of the proposed research is to determine the efficacy of a home-based walking exercise program in promoting cognitive-psychosocial functions of men with prostate cancer receiving androgen depletion therapy (ADT). ADT is the mainstay treatment for men with advanced prostate cancer. However, ADT has a number of side effects including compromised cognitive function, depression and anxiety, which negatively impacts the quality of life of men with prostate cancer. The central question of the proposed research is to determine if exercise will have a positive impact on the quality of life of men with prostate cancer undergoing ADT. Hypothesis:

Official Title
-----------------
Efficacy of Exercise in Promotion Cognitive-psychosocial Functions in Men With Prostate Cancer Receiving Androgen Depletion Therapy

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Behavioral: Exercise
* Behavioral: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men aged 50 or older diagnosed with adenocarcinoma prostate cancer will initiate and receive continuous ADT (LHRH or combination of LHRH and anti-androgen for at least 6 months Exclusion Criteria: severe cardiac disease (New York Heart Association class III or greater) angina severe osteoporosis uncontrolled hypertension orthostastic blood pressure drop > 20mm Hg moderate to severe aortic stenosis acute illness or fever uncontrolled atrial or ventricular dysrhythmias uncontrolled sinus tachycardia (> 120 beats per minute) uncontrolled congestive heart failure third-degree atrio-ventricular heart block active pericarditis or myocarditis recent embolism, thrombophlebitis deep vein thrombosis, resting ST displacement uncontrolled diabetes uncontrolled pain cognitive impairment history of falls due to balance impairment or lost of consciousness severe neuromusculoskeletal conditions that limit their ability to perform walking exercise

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise<br> | Behavioral: Exercise<br>* Home-base walking program<br>|
| No Intervention: Control<br> | Behavioral: Control<br>* Usual care<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive-psychosocial functions |  | 3 and 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| health-related quality of life |  | 3 and 6 months |
MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis

Study Overview
=================
Brief Summary
-----------------
Desmopressin in treatment of nocturnal enuresis (bedwetting).

Official Title
-----------------
MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis With Special Focus on Patient Satisfaction

Conditions
-----------------
Nocturnal Enuresis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Treatment of primary nocturnal enuresis within an overall therapeutical concept, eg, in cases of failure of other non-medicinal therapies or with indication of a medicinal therapy caused by nocturnal ADH deficiency The patients and their parents have been informed about the study and have given their written consent for participation. Exclusion Criteria: The prescription of Minirin® tablets / Minirin® orally disintegrating tablet (fast dissolving desmopressin) is contraindicated

Ages Eligible for Study
-----------------
Minimum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients treated with orally disintegrating tablet<br> | |
| Patients treated with tablets<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of patient and parent satisfaction |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of wet nights |  | 3 months | 
| Assessment of drinking volume |  | 3 months | 
| Assessment of urine volume |  | 3 months | 
| Assessment of patient compliance |  | 3 months |
Utility of PCD Diagnostics to Improve Clinical Care

Study Overview
=================
Brief Summary
-----------------
This is a study evaluating the utility of current Primary Ciliary Dyskinesia (PCD) diagnostic tests, including nasal nitric oxide testing.

Detailed Description
-----------------
This study is a prospective data collection of individuals referred to the investigators clinical center for considerations of PCD. Participants sign informed consent to have clinical information entered into a secure electronic database. As part of this study, participants may have nasal nitric oxide (nNO) testing performed. nNO testing is a research procedure, but it is a test with growing utility for making a diagnosis of PCD when performed in the right clinical setting.

Official Title
-----------------
Utility of PCD Diagnostics to Improve Clinical Care

Conditions
-----------------
Primary Ciliary Dyskinesia

Intervention / Treatment
-----------------
* Other: nNO testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Referred to center for PCD diagnosis considerations Ability to perform study procedures Age greater than 2 years of age Exclusion Criteria: Age less than 2 years of age Inability to perform informed consent

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Nasal Nitric Oxide testing and collection of clinical data<br>Participants will have nNO testing is indicated. All participants in this study have some basic clinical data collected at time of enrollment. Participants with a confirmed diagnosis of PCD or in those participants with a working diagnosis of PCD in which ongoing nNO testing is performed have prospective data collection. Some participants have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry and thus do not need nNO testing, but are followed prospectively with collection of basic clinical data | Other: nNO testing<br>* Collection of already performed clinical data and nNO testing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency of nNO tests performed | number of tests | 3 years | 
| Frequency of genetic tests performed | number of tests | 3 years |